Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 27, 2020	Mar. 29, 2019
Net sales		$ 665.8	$ 790.6
Operating Income (Loss)		(6.3)	15.4
Intangible asset amortization		(197.6)	(222.8)
Restructuring and related charges, net		1.8	(4.2)
Opioid-related litigation settlement (Note 11)		(16.8)	0.0
Specialty Brands
Restructuring and related charges, net		0.0	(0.5)
Specialty Generics
Restructuring and related charges, net		(0.1)	(3.5)
Operating Segments
Operating Income (Loss)		260.5	299.9
Operating Segments | Specialty Brands
Net sales		490.6	604.2
Operating Income (Loss)		212.2	275.5
Operating Segments | Specialty Generics
Net sales		175.2	186.4
Operating Income (Loss)		48.3	24.4
Corporate, Non-Segment
Corporate and unallocated expenses	[1]	(66.5)	(45.8)
Intangible asset amortization		(197.6)	(222.8)
Restructuring and related charges, net		1.8	(4.2)
Separation Costs	[2]	(21.3)	(11.7)
Opioid-related litigation settlement (Note 11)	[3]	$ 16.8	$ 0.0

[1] Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

[2] These costs, which are included in SG&A expenses, primarily relate to professional fees, incremental costs incurred to build out the corporate infrastructure of the previously planned spin-off of the Company's Specialty Generics segment, costs incurred as the Company works to resolve opioid uncertainties, as well as rebranding initiatives associated with the Specialty Brands ongoing transformation.

[3] Represents the change in the Settlement Warrants' fair value. Refer to Note 12 for further information regarding the valuations of the Settlement Warrants.